Pneumococcal conjugate vaccines (PCVs) have helped reduce childhood deaths and illness, however, they are among the most complicated and expensive vaccines to manufacture. Millions of children still either don’t have or are at risk of losing access to PCVs. Vaccine price is at the heart of the problem.
This is why PATH, the Serum Institute of India, and other partners spent a decade developing PNEUMOSIL, a safe, effective, and affordable PCV that focuses on the varieties of pneumonia that threaten children in underserved countries. PNEUMOSIL is priced at just $2 per dose for low- and middle-income countries—significantly less than typical PCV prices. This lifesaving vaccine is poised to reach more children by breaking down price barriers to access.
PNEUMOSIL is an important milestone toward alleviating the price and supply barriers that have historically hindered or precluded sustainable access for people in low- and middle-income countries. It is already saving more lives by enhancing global protection against pneumococcal disease, including pneumonia—the #1 infectious killer of children worldwide. But this is only the beginning.
A worker at Serum Institute of India inspects vaccine vials at the company’s vaccine manufacturing division where PNEUMOSIL® and other conjugate vaccines are made. Photo: PATH/Satvir Malhotra
Help us continue this work.
With your support, PATH can continue scaling access to PNEUMOSIL and other lifesaving solutions for the children, families, and communities around the world who need them most.